MMMohapradeep Mohan

Mohapradeep Mohan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohapradeep Mohan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin Ian Perry

    2 shared publications
  • Swaran Preet Singh

    2 shared publications
  • Adel Dihoum

    Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, United Kingdom

    1 shared publication
  • Anna-Maria Choy

    Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, United Kingdom

    1 shared publication
  • Chim C. Lang

    Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, United Kingdom

    1 shared publication
  • Graham Rena

    Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention

    by Mohapradeep Mohan, Adel Dihoum, Ify R. Mordi, Anna-Maria Choy, Graham Rena, Chim C. Lang

    Heart failure is an important manifestation of diabetic heart disease. Before the development of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus (T2DM) develop asymptomatic left ventricular dysfunction including left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) is highly prevalent in patients with T2DM and is a strong predictor of adverse cardiovascular outcomes including heart failure. Importantly regression of LVH with antihypertensive treatment especially renin angiotensin system blockers reduces cardiovascular morbidity and mortality. However, this approach is only partially effective since LVH persists in 20% of patients with hypertension who attain target blood pressure, implicating the role of other potential mechanisms in the development of LVH. Moreover, the pathophysiology of LVH in T2DM remains unclear and is not fully explained by the hyperglycemia-associated cellular alterations. There is a growing body of evidence that supports the role of inflammation, oxidative stress, AMP-activated kinase (AMPK) and insulin resistance in mediating the development of LVH. The recognition of asymptomatic LVH may offer an opportune target for intervention with cardio-protective therapy in these at-risk patients. In this article, we provide a review of some of the key clinical studies that evaluated the effects of allopurinol, SGLT2 inhibitor and metformin in regressing LVH in patients with and without T2DM.


  • Open Access

    COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis

    by Mohapradeep Mohan, Benjamin Ian Perry, Ponnusamy Saravanan, Swaran Preet Singh

  • Open Access

    COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis

    by Mohapradeep Mohan, Benjamin Ian Perry, Ponnusamy Saravanan, Swaran Preet Singh

    As the global burden of mortality from COVID-19 continues to rise, an understanding of who is most at risk of adverse outcomes is of paramount importance. Pre-existing cardiometabolic, renal and respiratory diseases as well as old age are well-established risk factors associated with disease severity and mortality among patients with COVID-19. However, mounting evidence also indicates an increased susceptibility to, and risk of adverse outcomes from COVID-19 in people with schizophrenia, independent of age and comorbidity. Therefore, elucidating the underlying pathophysiological mechanisms which may increase the risk of poor outcomes in people with schizophrenia is of crucial importance. Here, we provide a narrative on the current understanding of COVID-19 in patients with schizophrenia and propose potential mechanisms which may link schizophrenia with an increased susceptibility to, and greater risk of adverse outcomes from COVID-19. Given the existing knowledge gaps, robust clinical and biological studies are required to further our understanding of some of these underlying mechanisms, so that effective prevention and treatment strategies for COVID-19 in patients with schizophrenia can be developed.